SL Science Holding Limited - SIC # 2840 -

Ticker Exchange SIC # Website Latest Ticker
SLBT Nasdaq 2840 www.sl-bio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for SL Science Holding Limited

SL Science Highlights New FDA Drug Master File for GDT Cell-Derived Exosomes, Expanding the Regulatory Foundation of its Platform - Aug 27th, 2026 6:00 am
SL Science Holding (SLBT) Stock May Be Fully Priced Even After A 74% Fall - Aug 18th, 2026 11:13 am
SL Science Leadership Co-Authors Peer-Reviewed Framework for Clinical Development of γδ T Cell Therapy in Glioblastoma - Aug 11th, 2026 6:00 am
SL Science Announces Successful Exhibition of Breakthrough Brain Cancer Therapy Research at the 2026 World Congress of Basic and Clinical Pharmacology - Jul 17th, 2026 6:00 am
Sector Update: Healthcare Stocks Decline Late Afternoon - Jul 10th, 2026 1:50 pm
SL Science Holding Limited Submits Orphan Drug Designation Request to the U.S. FDA for GDT Cell Therapy Targeting Glioblastoma - Jul 10th, 2026 6:00 am
Top Midday Decliners - Jun 22nd, 2026 12:06 pm
SL Science Holding Limited Reports Full Year 2025 Financial Results - Jun 18th, 2026 3:13 pm